Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | BTK T474S BTK C481S |
Therapy | Fenebrutinib |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BTK T474S BTK C481S | Advanced Solid Tumor | predicted - sensitive | Fenebrutinib | Preclinical - Biochemical | Actionable | In a preclinical study, treatment with Fenebrutinib (GDC-0853) resulted in reduced Btk activity in a cell line expressing BTK variants T474S and C481S in culture (PMID: 33526860). | 33526860 |
PubMed Id | Reference Title | Details |
---|---|---|
(33526860) | BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib. | Full reference... |